COMPOSITION | |
---|---|
Terbutaline | 1.25 MG |
Bromhexine Hydrochloride | 2 MG |
Guaiphenesin | 50 MG |
Menthol | 0.5 MG |
Terbutaline ,Bromhexine Hydrochloride ,Guaiphenesin & Menthol
MUCOVIB
SPECIFICATION | |
---|---|
FORM | SYRUP |
PACKING | 100ml |
PACKING TYPE | |
MRP | 49.9 |
DESCRIPTION
Terbutaline Sulphate + Guaiphenesin + Bromhexine Hydrochloride + Menthol Suspension:
Terbutaline Sulphate is a selective beta2 -adrenergic agonist which predominantly stimulates beta2-receptors, thus producing relaxation of bronchial smooth muscle. Guaiphenesin, by increasing respiratory tract fluid, reduces the viscosity of tenacious secretions and acts as an expectorant. Bromhexine HCl is intended to support the body’s mechanisms for clearing mucus from the respiratory tract. It is secretolytic, increasing the production of serous mucus in the respiratory tract and makes the phlegm thinner and less viscous Menthol is also classified as a expectorant.
RATIONALE OF COMBINATION
Terbutaline sulphate relaxes bronchial muscles and Guaiphenesin along with Menthol acts as a expectorant reducing the viscosity and helps to loosens mucus in your lungs. Whereas,
Bromhexine is an expectorant/mucolytic agent. Bromhexine is not available in the United States. It is marketed under the trade name Bisolvon(R) in Germany, England, Belgium, France, Italy, Netherlands, Norway, Sweden, Australia, and South Africa.
INDICATION
Increased heart rate
Palpitations
Dizziness
Headache
Drownsiness
Vomitting/Nausea
Gastrointestinal discomfort.
INDICATION
Cough associated with Acute and Chronic Bronchitis
Asthmatic Bronchitis
Emphysema, Active and Passive Smoking
Pulmonary TB
Other Bronchospastic Disorders